INCY

Incyte Corporation · Healthcare · Biotechnology
$114.88
+0.65 (+0.57%)
Mkt Cap: 22.95B
Key Metrics
MetricValue
P/E RatioN/A
EV/EBITDAN/A
ROEN/A
Gross MarginN/A
Revenue GrowthN/A
FCF Yield7.0%
Dividend YieldN/A
Market Cap22.95B
Volume1.30M
Recent News
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
gurufocus.com · 2026-07-13
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
businesswire.com · 2026-07-13
2 Fast-Growing Pharmaceutical Stocks to Buy Now
fool.com · 2026-07-08
Incyte to Report Second Quarter Financial Results
businesswire.com · 2026-07-08
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
businesswire.com · 2026-07-06
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion
fxempire.com · 2026-07-03

Unlock the Full Deep Scan

9 AI agents analyze INCY across earnings, insider flow, macro conditions, corporate strategy, market microstructure, and price action.

Sign Up Free →